| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Helicobacter Infections | 22 | 2016 | 55 | 3.820 |
Why?
|
| Stomach Neoplasms | 19 | 2018 | 83 | 3.450 |
Why?
|
| Bone Marrow Cells | 10 | 2016 | 237 | 1.850 |
Why?
|
| Helicobacter felis | 12 | 2013 | 17 | 1.830 |
Why?
|
| Gastric Mucosa | 15 | 2016 | 53 | 1.570 |
Why?
|
| Helicobacter pylori | 12 | 2016 | 58 | 1.460 |
Why?
|
| Adenocarcinoma | 7 | 2018 | 349 | 1.080 |
Why?
|
| fas Receptor | 4 | 2009 | 57 | 1.030 |
Why?
|
| Cell Transformation, Neoplastic | 9 | 2014 | 205 | 0.950 |
Why?
|
| Gastritis | 6 | 2014 | 17 | 0.930 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 308 | 0.860 |
Why?
|
| Stromal Cells | 4 | 2014 | 69 | 0.840 |
Why?
|
| Epithelial Cells | 6 | 2016 | 392 | 0.720 |
Why?
|
| Helicobacter | 2 | 2012 | 3 | 0.670 |
Why?
|
| Animals | 42 | 2023 | 20715 | 0.660 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 221 | 0.640 |
Why?
|
| Mice | 29 | 2023 | 10863 | 0.630 |
Why?
|
| Cell Proliferation | 9 | 2021 | 988 | 0.630 |
Why?
|
| Neoplastic Stem Cells | 4 | 2011 | 199 | 0.590 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 385 | 0.560 |
Why?
|
| Precancerous Conditions | 4 | 2018 | 71 | 0.560 |
Why?
|
| Inflammation | 8 | 2023 | 1146 | 0.540 |
Why?
|
| Mice, Inbred C57BL | 15 | 2021 | 3401 | 0.510 |
Why?
|
| Disease Models, Animal | 8 | 2014 | 2196 | 0.440 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2014 | 78 | 0.420 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 36 | 0.410 |
Why?
|
| Stem Cells | 2 | 2006 | 261 | 0.400 |
Why?
|
| Signal Transduction | 10 | 2014 | 3033 | 0.400 |
Why?
|
| Apoptosis | 6 | 2009 | 1080 | 0.390 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 268 | 0.380 |
Why?
|
| Neoplasms | 3 | 2007 | 1376 | 0.370 |
Why?
|
| Colitis | 2 | 2023 | 77 | 0.350 |
Why?
|
| Fas Ligand Protein | 2 | 2009 | 42 | 0.350 |
Why?
|
| Endothelium | 1 | 2010 | 21 | 0.340 |
Why?
|
| Myofibroblasts | 1 | 2010 | 16 | 0.340 |
Why?
|
| Barrett Esophagus | 1 | 2010 | 30 | 0.330 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2010 | 29 | 0.330 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 79 | 0.330 |
Why?
|
| Cytokines | 7 | 2020 | 934 | 0.320 |
Why?
|
| Liver Neoplasms | 2 | 2009 | 301 | 0.310 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 38 | 0.310 |
Why?
|
| Mucins | 3 | 2006 | 26 | 0.300 |
Why?
|
| Gastrins | 6 | 2014 | 6 | 0.300 |
Why?
|
| Tea | 1 | 2009 | 32 | 0.290 |
Why?
|
| Muscle Proteins | 3 | 2006 | 117 | 0.290 |
Why?
|
| Humans | 32 | 2021 | 63545 | 0.280 |
Why?
|
| Mutation | 2 | 2021 | 2615 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 42 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 3 | 2009 | 791 | 0.270 |
Why?
|
| Hedgehog Proteins | 3 | 2014 | 111 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 45 | 0.270 |
Why?
|
| Genes, p53 | 1 | 2007 | 51 | 0.270 |
Why?
|
| Plant Extracts | 1 | 2009 | 172 | 0.260 |
Why?
|
| Point Mutation | 1 | 2007 | 166 | 0.260 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 183 | 0.260 |
Why?
|
| Immunity, Innate | 3 | 2021 | 797 | 0.260 |
Why?
|
| Male | 18 | 2021 | 29943 | 0.250 |
Why?
|
| Stomach | 4 | 2018 | 88 | 0.250 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 14 | 0.240 |
Why?
|
| Receptor Aggregation | 1 | 2005 | 5 | 0.240 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 662 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 527 | 0.220 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2005 | 182 | 0.220 |
Why?
|
| Toxoplasmosis | 1 | 2004 | 20 | 0.220 |
Why?
|
| Mice, Knockout | 7 | 2016 | 2113 | 0.220 |
Why?
|
| Toxoplasma | 1 | 2004 | 33 | 0.220 |
Why?
|
| Actins | 1 | 2005 | 260 | 0.210 |
Why?
|
| Cell Differentiation | 5 | 2013 | 1355 | 0.210 |
Why?
|
| Lymphocytes | 2 | 2020 | 202 | 0.210 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2166 | 0.200 |
Why?
|
| Mice, SCID | 3 | 2014 | 516 | 0.190 |
Why?
|
| Mice, Inbred NOD | 3 | 2014 | 523 | 0.190 |
Why?
|
| Metaplasia | 3 | 2010 | 18 | 0.190 |
Why?
|
| Cell Line, Tumor | 4 | 2011 | 1470 | 0.190 |
Why?
|
| Blood Bactericidal Activity | 1 | 2002 | 62 | 0.180 |
Why?
|
| Neuropeptides | 1 | 2002 | 81 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2002 | 79 | 0.170 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 170 | 0.170 |
Why?
|
| Ubiquitination | 1 | 2021 | 113 | 0.170 |
Why?
|
| Myeloid Cells | 1 | 2021 | 94 | 0.170 |
Why?
|
| Fibroblasts | 2 | 2014 | 397 | 0.170 |
Why?
|
| Dysbiosis | 1 | 2021 | 65 | 0.160 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2020 | 10 | 0.160 |
Why?
|
| Peptides | 4 | 2018 | 574 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 3 | 2016 | 140 | 0.150 |
Why?
|
| Interferon-gamma | 4 | 2018 | 566 | 0.150 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 2 | 2009 | 9 | 0.150 |
Why?
|
| Mice, Transgenic | 5 | 2016 | 1284 | 0.150 |
Why?
|
| Transfection | 3 | 2011 | 695 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 216 | 0.150 |
Why?
|
| Coculture Techniques | 3 | 2011 | 97 | 0.140 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 73 | 0.140 |
Why?
|
| Epithelium | 2 | 2010 | 96 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 896 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 237 | 0.130 |
Why?
|
| Atrophy | 3 | 2006 | 83 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 616 | 0.130 |
Why?
|
| Fluorouracil | 2 | 2014 | 66 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2016 | 31 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2018 | 130 | 0.130 |
Why?
|
| Disease Progression | 3 | 2007 | 1170 | 0.130 |
Why?
|
| Female | 8 | 2021 | 32949 | 0.120 |
Why?
|
| Receptors, Histamine H2 | 2 | 2006 | 2 | 0.120 |
Why?
|
| Trefoil Factor-2 | 3 | 2006 | 6 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2021 | 899 | 0.120 |
Why?
|
| Homeostasis | 3 | 2023 | 369 | 0.110 |
Why?
|
| HIV-1 | 1 | 2020 | 723 | 0.110 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2014 | 42 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 42 | 0.110 |
Why?
|
| Time Factors | 4 | 2011 | 3708 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2009 | 719 | 0.100 |
Why?
|
| Rats | 2 | 2007 | 1991 | 0.100 |
Why?
|
| Intestinal Mucosa | 3 | 2023 | 242 | 0.100 |
Why?
|
| Middle Aged | 5 | 2014 | 17662 | 0.090 |
Why?
|
| Organelles | 1 | 2011 | 20 | 0.090 |
Why?
|
| Cellular Reprogramming | 1 | 2011 | 37 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 78 | 0.090 |
Why?
|
| Models, Biological | 2 | 2007 | 1182 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 448 | 0.080 |
Why?
|
| Genes, APC | 1 | 2010 | 10 | 0.080 |
Why?
|
| Culture Media, Conditioned | 1 | 2010 | 51 | 0.080 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 157 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 197 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 166 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 248 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 37 | 0.080 |
Why?
|
| Ethanol | 1 | 2013 | 322 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 45 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 490 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 167 | 0.080 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2011 | 150 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 302 | 0.080 |
Why?
|
| Mammary Glands, Animal | 1 | 2010 | 79 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 239 | 0.080 |
Why?
|
| Receptor, Cholecystokinin B | 2 | 2006 | 2 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 48 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2010 | 175 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 185 | 0.080 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 39 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2009 | 61 | 0.080 |
Why?
|
| Autophagy | 1 | 2011 | 226 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 347 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2009 | 190 | 0.070 |
Why?
|
| Aged | 4 | 2014 | 14454 | 0.070 |
Why?
|
| Hepatitis | 1 | 2009 | 57 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 456 | 0.070 |
Why?
|
| Gastritis, Atrophic | 2 | 2010 | 3 | 0.070 |
Why?
|
| Cell Movement | 1 | 2010 | 457 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 212 | 0.070 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2007 | 4 | 0.070 |
Why?
|
| Fibrosarcoma | 1 | 2007 | 14 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 265 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 99 | 0.070 |
Why?
|
| Hepatocytes | 1 | 2009 | 218 | 0.070 |
Why?
|
| Cell Division | 2 | 2011 | 452 | 0.070 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2007 | 82 | 0.070 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2009 | 102 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2007 | 78 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 356 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2007 | 190 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 71 | 0.060 |
Why?
|
| Adult | 4 | 2010 | 16906 | 0.060 |
Why?
|
| Drug Design | 1 | 2007 | 136 | 0.060 |
Why?
|
| Cytochalasin D | 1 | 2005 | 18 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 277 | 0.060 |
Why?
|
| Benzodiazepinones | 1 | 2005 | 2 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2007 | 469 | 0.060 |
Why?
|
| Antioxidants | 1 | 2007 | 252 | 0.060 |
Why?
|
| Tetracycline | 1 | 2005 | 24 | 0.060 |
Why?
|
| Histamine H2 Antagonists | 1 | 2005 | 16 | 0.060 |
Why?
|
| Phenylurea Compounds | 1 | 2005 | 31 | 0.060 |
Why?
|
| Adipocytes | 1 | 2007 | 268 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2007 | 937 | 0.060 |
Why?
|
| Triazoles | 1 | 2005 | 56 | 0.060 |
Why?
|
| Parietal Cells, Gastric | 1 | 2004 | 1 | 0.060 |
Why?
|
| Helicobacter hepaticus | 1 | 2004 | 2 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 863 | 0.060 |
Why?
|
| Keratins | 1 | 2004 | 31 | 0.060 |
Why?
|
| Cell Fusion | 1 | 2004 | 39 | 0.060 |
Why?
|
| Intestines | 2 | 2021 | 165 | 0.050 |
Why?
|
| Carcinoma in Situ | 1 | 2004 | 35 | 0.050 |
Why?
|
| Virulence | 1 | 2004 | 193 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2006 | 271 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1185 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2004 | 197 | 0.050 |
Why?
|
| Glycine | 1 | 2004 | 49 | 0.050 |
Why?
|
| Cadherins | 1 | 2003 | 80 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 165 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 5468 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 460 | 0.050 |
Why?
|
| Trefoil Factor-3 | 1 | 2002 | 2 | 0.050 |
Why?
|
| Gastric Acid | 1 | 2002 | 10 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 34 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 429 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2003 | 159 | 0.050 |
Why?
|
| Urease | 1 | 2002 | 9 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2002 | 63 | 0.050 |
Why?
|
| Colony Count, Microbial | 1 | 2002 | 59 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2002 | 61 | 0.050 |
Why?
|
| Culture Media | 1 | 2002 | 79 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 259 | 0.040 |
Why?
|
| RNA Interference | 2 | 2018 | 618 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1204 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 669 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 491 | 0.040 |
Why?
|
| Macrophages | 1 | 2006 | 1041 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2002 | 243 | 0.040 |
Why?
|
| Phenotype | 1 | 2004 | 1208 | 0.040 |
Why?
|
| Biopsy | 1 | 2002 | 447 | 0.040 |
Why?
|
| Acute Disease | 1 | 2002 | 669 | 0.040 |
Why?
|
| Mitochondria | 1 | 2023 | 372 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 81 | 0.040 |
Why?
|
| Monocytes | 1 | 2021 | 353 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 490 | 0.040 |
Why?
|
| Neutrophils | 1 | 2002 | 376 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1151 | 0.040 |
Why?
|
| Diet | 1 | 2002 | 527 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1120 | 0.030 |
Why?
|
| Interleukins | 1 | 2018 | 80 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2020 | 288 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2018 | 61 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 182 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 685 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2018 | 173 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 152 | 0.030 |
Why?
|
| Mosaicism | 1 | 2016 | 30 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 883 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2018 | 237 | 0.030 |
Why?
|
| Microbiota | 1 | 2018 | 129 | 0.030 |
Why?
|
| Cell Line | 2 | 2011 | 2041 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 18 | 0.030 |
Why?
|
| Focal Adhesions | 1 | 2013 | 24 | 0.030 |
Why?
|
| Risk Factors | 1 | 2003 | 5282 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1617 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 202 | 0.020 |
Why?
|
| HIV Infections | 1 | 2020 | 972 | 0.020 |
Why?
|
| Succinimides | 1 | 2011 | 17 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2011 | 30 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 21 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 92 | 0.020 |
Why?
|
| Centrosome | 1 | 2011 | 71 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 190 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 401 | 0.020 |
Why?
|
| Lysosomes | 1 | 2011 | 166 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 200 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 536 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 171 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 78 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 337 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 58 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 177 | 0.020 |
Why?
|
| Rituximab | 1 | 2009 | 88 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 395 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 373 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 244 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 458 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 374 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 264 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 498 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 517 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 853 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 778 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2006 | 66 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 104 | 0.020 |
Why?
|
| Proteins | 1 | 2011 | 753 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 455 | 0.010 |
Why?
|
| Achlorhydria | 1 | 2005 | 1 | 0.010 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2005 | 2 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 297 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 545 | 0.010 |
Why?
|
| Macrophages, Peritoneal | 1 | 2004 | 77 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2004 | 222 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 843 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 769 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 344 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 431 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 584 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 172 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 623 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 4720 | 0.010 |
Why?
|
| Prognosis | 1 | 2004 | 1743 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 5628 | 0.010 |
Why?
|